Serial KL-6 Changes in PD-1/PD-L1 Inhibitor-Related Pneumonitis in Non-small Cell Lung Cancer: A Single-Center...

Area of Science:

• Oncology
• Pulmonology
• Immunotherapy

Background:

• Programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) inhibitors are crucial for non-small cell lung cancer (NSCLC) treatment.
• PD-1/PD-L1 inhibitor therapy can cause severe pneumonitis, necessitating reliable diagnostic markers.
• Krebs von den Lungen-6 (KL-6) is a biomarker investigated for lung disease prediction.

Purpose of the Study:

• To evaluate the predictive and diagnostic utility of KL-6 for PD-1/PD-L1 inhibitor-related pneumonitis in NSCLC patients.
• To assess the correlation between KL-6 levels and the development of pneumonitis during immunotherapy.

Main Methods:

• A prospective observational study was conducted with 18 NSCLC patients undergoing PD-1/PD-L1 inhibitor therapy.
• Baseline KL-6 levels were measured before treatment initiation.
• Serial KL-6 measurements were performed during and after treatment, with specific monitoring for patients developing pneumonitis.

Main Results:

• No significant difference in baseline KL-6 levels was observed between patients who developed pneumonitis and those who did not.
• Patients who developed pneumonitis showed a general upward trend in KL-6 levels, with a median of 412 U/mL at onset.
• The non-pneumonitis group did not exhibit a clear overall change in KL-6 levels.

Conclusions:

• Baseline KL-6 levels are not clearly associated with the risk of PD-1/PD-L1 inhibitor-related pneumonitis in NSCLC.
• Post-baseline increases in KL-6 levels were more frequent in patients who developed pneumonitis.
• Further research is warranted to fully understand KL-6's role in monitoring immunotherapy-induced lung injury.